These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33968273)

  • 1. A 4-Year Follow-Up of Subjects with Visually Equivocal Amyloid Positron Emission Tomography Findings from the Alzheimer's Disease Neuroimaging Initiative Cohort.
    Oh M; Seo M; Oh SY; Kim H; Choi BW; Oh JS; Kim JS;
    Nucl Med Mol Imaging; 2021 Apr; 55(2):71-78. PubMed ID: 33968273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study.
    Okada Y; Kato T; Iwata K; Kimura Y; Nakamura A; Hattori H; Toyama H; Ishii K; Ishii K; Senda M; Ito K; Iwatsubo T;
    Ann Nucl Med; 2020 Feb; 34(2):108-118. PubMed ID: 31749127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of visually equivocal amyloid PET findings from the Alzheimer's Disease Neuroimaging Initiative cohort.
    Oh M; Seo M; Oh SY; Kim H; Choi BW; Oh JS; Kim JS;
    Neuroreport; 2018 May; 29(7):553-558. PubMed ID: 29438267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
    Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
    JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings.
    Payoux P; Delrieu J; Gallini A; Adel D; Salabert AS; Hitzel A; Cantet C; Tafani M; De Verbizier D; Darcourt J; Fernandez P; Monteil J; Carrié I; Voisin T; Gillette-Guyonnet S; Pontecorvo M; Vellas B; Andrieu S
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1459-68. PubMed ID: 25952279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
    Camus V; Payoux P; Barré L; Desgranges B; Voisin T; Tauber C; La Joie R; Tafani M; Hommet C; Chételat G; Mondon K; de La Sayette V; Cottier JP; Beaufils E; Ribeiro MJ; Gissot V; Vierron E; Vercouillie J; Vellas B; Eustache F; Guilloteau D
    Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):621-31. PubMed ID: 22252372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
    Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
    Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic value of amyloid PET textural and shape features: comparison with classical semi-quantitative rating in 760 patients from the ADNI-2 database.
    Ben Bouallègue F; Vauchot F; Mariano-Goulart D; Payoux P
    Brain Imaging Behav; 2019 Feb; 13(1):111-125. PubMed ID: 29427064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
    Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
    BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical feasibility of deep learning-based classification of amyloid PET images in visually equivocal cases.
    Son HJ; Oh JS; Oh M; Kim SJ; Lee JH; Roh JH; Kim JS
    Eur J Nucl Med Mol Imaging; 2020 Feb; 47(2):332-341. PubMed ID: 31811343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
    Palmqvist S; Mattsson N; Hansson O;
    Brain; 2016 Apr; 139(Pt 4):1226-36. PubMed ID: 26936941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inter-rater variability of visual interpretation and comparison with quantitative evaluation of
    Yamane T; Ishii K; Sakata M; Ikari Y; Nishio T; Ishii K; Kato T; Ito K; Senda M;
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):850-857. PubMed ID: 27966045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Evaluation of
    Matsuda H; Ito K; Ishii K; Shimosegawa E; Okazawa H; Mishina M; Mizumura S; Ishii K; Okita K; Shigemoto Y; Kato T; Takenaka A; Kaida H; Hanaoka K; Matsunaga K; Hatazawa J; Ikawa M; Tsujikawa T; Morooka M; Ishibashi K; Kameyama M; Yamao T; Miwa K; Ogawa M; Sato N
    Front Neurol; 2020; 11():578753. PubMed ID: 33519667
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
    Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.